Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Coiffier, Bertrand; Thiéblemont, Catherine; Neste, Éric Van Den; Lepeu, G.; Plantier, Isabelle; Castaigné, Sylvie; Lefort, Sophie; Marit, Gérald; Macro, Margaret; Sebban, Catherine; Belhadj, Karim; Bron, Dominique; Fermé, Christophe; Tilly, Hervé

doi:10.1182/blood-2010-03-276246

Cited by 1,284 publications

(938 citation statements)

References 13 publications

Supporting

Mentioning

882

Contrasting

Unclassified

Order By: Relevance

“…A pivotal trial done in 1998 by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) showed that combining rituximab with standard cyclophospha mide, doxorubicin, vincristine, and predni sone (CHOP) chemo therapy signifi cantly improved response, event-free survival, and overall survival compared with CHOP alone in patients older than 60 years. 2,3 These favourable results have been confi rmed by three additional randomised trials in patients both younger and older than 60 years with diff use large B-cell lymphoma. [4][5][6] However, despite these signifi cant improve ments, some patients are refractory to initial treatment or can relapse after a complete response.…”

Section: Introductionmentioning

confidence: 89%

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 89%

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall response rates (ORR) can reach 75% (Coiffier et al , 2010). However, there is less consensus on salvage regimens for the 25–35% of patients who fail to respond or relapse after first‐line therapy with standard protocols.…”

mentioning

confidence: 99%

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

et al. 2016

Self Cite

View full text Add to dashboard Cite

This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma (NHL) confirmed by centralized histological review. Patients received 28‐d cycles of 85 mg/m2 pixantrone dimaleate (equivalent to 50 mg/m2 in the approved formulation) on days 1, 8 and 15, or comparator. The population was subdivided according to previous rituximab use and whether they received the study treatment as 3rd or 4th line. Median number of cycles was 4 (range, 2–6) with pixantrone and 3 (2–6) with comparator. In 3rd or 4th line, pixantrone was associated with higher complete response (CR) (23·1% vs. 5·1% comparator, P = 0·047) and overall response rate (ORR, 43·6% vs. 12·8%, P = 0·005). In 3rd or 4th line with previous rituximab (20 pixantrone, 18 comparator), pixantrone produced better ORR (45·0% vs. 11·1%, P = 0·033), CR (30·0% vs. 5·6%, P = 0·093) and progression‐free survival (median 5·4 vs. 2·8 months, hazard ratio 0·52, 95% confidence interval 0·26–1·04) than the comparator. Similar results were found in patients without previous rituximab. There were no unexpected safety issues. Pixantrone monotherapy is more effective than comparator in relapsed or refractory aggressive B‐cell NHL in the 3rd or 4th line setting, independently of previous rituximab.

show abstract

“…5 With the development of anti-CD20 monoclonal antibody rituximab, CHOP plus rituximab (R-CHOP) regimen replaced CHOP, based on the improved complete remission rate and event-free survival rate of R-CHOP, currently the standard treatment for diffuse large B-cell lymphoma. [6][7][8][9] However, despite many breakthroughs in the treatment of diffuse large B-cell lymphoma, up to onethird of diffuse large B-cell lymphoma patients still suffer from relapse or primary refractory disease. 10 The variable clinical presentations of diffuse large B-cell lymphoma reflect the disease's molecular heterogeneity.…”

mentioning

confidence: 99%

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

et al. 2015

View full text Add to dashboard Cite

Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of 425%, associated with an International Prognostic Index score of 42 (P = 0.015), disease in ≥ 2 extranodal sites (P = 0.011), and a high Ki-67 index (Po 0.0001). Among patients with activated B cell-like disease, the overall survival rate of survivin-positive patients was significantly lower than that of survivinnegative patients (P = 0.033); multivariate analysis confirmed that in these patients, survivin overexpression was an independent prognostic factor for survival. Among patients with wild-type p53 overexpression, the overall survival and progression-free survival rates of the survivin-positive group were significantly lower than those of the survivin-negative group (P = 0.035 and P = 0.04 respectively). In STAT3-positive patients, survivin overexpression was associated with significantly better survival. Among patients with activated B cell-like disease, survivin-positive compared with survivin-negative groups had significantly different gene expression signatures, including genes involved in mitosis or tumor cell proliferation. Our results indicate that survivin is an

show abstract

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Cited by 1,284 publications

References 13 publications

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Contact Info

Product

Resources

About